Rofecoxib and celecoxib demonstrate similar, significant 6-week efficacy vs placebo in OA treatment .
Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies
Curr Med Res Opin. 2006 Jan;22(1):199-210808 patients, combined from two trials, with knee osteoarthritis were randomized to receive either celecoxib 200mg daily, rofecoxib 12.5mg daily, or placebo. Patients were assessed over a 6-week period of treatment on a Patient Global Assessment of Response to Therapy (PGART), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and Physical Function subscales, and the incidence of adverse events. Both celecoxib and rofecoxib were associated with significantly better results regarding PGART and WOMAC score compared to placebo. No significant differences were noted in the incidence of adverse events. Readers should note that since the time of publication, rofecoxib has been withdrawn from the market due to concerns regarding cardiovascular safety.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
